1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Healthcare Information Services
Cogstate Limited

Cogstate Limited

CGS.AX
Cogstate LimitedAU flagAustralian Securities Exchange
2.80
AUD
-0.03
- -
475.68MMarket Cap
Cogstate Limited
CGS.AX
(Australian Securities Exchange)

Recent

price

2.80

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.12
0.13
0.16
0.15
0.13
0.12
0.18
0.24
0.25
0.18
0.15
0.19
0.26
0.23
0.25
0.3
Revenue per Share
0.02
-0.01
0.03
-0.02
-0.04
-0.04
0.02
-0.01
- -
-0.02
-0.01
0.03
0.04
0.02
0.03
0.06
Basic EPS, GAAP
0.01
0.01
0.01
-0.03
-0.05
-0.04
0.01
0.01
-0.02
-0.02
-0.02
-0.02
-0.02
-0.01
-0.01
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.07
0.08
0.12
0.09
0.12
0.07
0.09
0.09
0.11
0.09
0.11
0.14
0.19
0.21
0.23
0.25
Book Value per Share
0.08
0.09
0.1
0.08
0.11
0.07
0.09
0.09
0.08
0.04
0.06
0.08
0.13
0.15
0.18
0.22
Tangible Book Value per Share
67
68
75
77
91
100
111
114
115
119
159
170
173
173
172
171
Basic Weighted Avg Shares
8
9
12
11
12
12
20
27
29
22
24
33
45
40
43
51
Sales/Revenue/Turnover
2.82
-2.68
11.94
-19.62
-38.89
-26.96
2.57
-1.41
0.63
-26.8
-8.13
11.71
24.14
5.57
14.21
21.25
Operating Margin (%)
- -
- -
1
1
1
1
1
1
1
- -
2
2
2
3
3
3
Depreciation Expense
1
-1
3
-2
-4
-4
2
-1
-1
-2
-1
5
8
4
5
10
Net Income, GAAP
- -
- -
12.19
- -
- -
- -
- -
- -
632.79
- -
- -
10.09
29.67
- -
23.26
27.06
Effective Tax Rate (%)
17.27
-10.4
20.41
-15.7
-31.7
-31.49
9.69
-2.36
-1.95
-11.43
-5.56
16.01
16.72
8.82
12.55
19.97
Profit Margin (%)
3
4
5
5
8
6
6
7
6
- -
3
15
24
26
31
37
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
1
- -
- -
- -
LT Debt
6
7
10
8
12
8
10
11
12
10
16
22
33
38
41
48
Total Equity
- -
- -
14.98
- -
- -
- -
- -
- -
-8.59
- -
- -
15.39
26.4
- -
11.89
17.35
Return on Invested Capital (%)
- -
- -
35.58
- -
- -
- -
- -
- -
-8.56
- -
- -
22.4
25.58
- -
14.42
24.41
Return on Capital (%)
34.32
-17.82
34.94
-22.39
-41.98
-43.92
23.24
-6.37
-5.03
-21.12
-9.2
25.74
26.8
10.33
14.52
24.61
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.81%
25.26%
17.05%
Free Cash Flow
-35.55%
4.7%
62.79%
Net Income, GAAP
-36.75%
-73.54%
86.15%
Sales/Revenue/Turnover
17.86%
17.98%
17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
40
2024
- -
- -
- -
- -
43
2025
- -
- -
- -
- -
51

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.02
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.06

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
TALi Digital Limited (TD1.AX)
MultiPlan Corporation (MPLN)
MSP Recovery, Inc. (LIFW)
Oakridge International Limited (U9O0.F)
Aspyra Inc. (APYI)
Aino Health AB (publ) (AINO.ST)
Business
Cogstate Limited (ASX: CGS) is a neuroscience technology company that creates, validates, and commercializes digital brain health assessments worldwide; designs and provides quality assurance services in clinical trials focused on the administration, scoring, and recording of conventional brain health assessments; and offers scientific consulting, project management, data management, statistical analysis, and reporting. The company provides computerized cognitive tests across domains including Alzheimer's disease and dementia, preclinical Alzheimer's, pediatrics and rare diseases, Parkinson's disease, multiple sclerosis, schizophrenia, oncology, safety, sleep, and mood disorders; supports electronic clinical outcome assessment (eCOA) solutions; delivers remote assessment capabilities; and supplies healthcare cognitive screening tools alongside research and academic collaboration solutions. Founded in 1999 and headquartered in Melbourne, Australia, with key offices in New Haven, Connecticut, and London, Cogstate operates primarily in the clinical trials, healthcare, and academic research segments, serving biopharmaceutical companies, physicians, and institutions across multiple continents. In fiscal year 2025, the company reported record revenue growth of 22% driven by a 28% increase in clinical trials revenue to $50.6 million, alongside EBITDA expansion of 72%; entered a strategic partnership with Medidata in October 2024 to expand reach in central nervous system clinical research; prepared to launch its first AI-powered products in fiscal year 2026 to enhance data quality and signal detection; and declared its maiden dividend while securing $35.9 million in revenue under contract entering fiscal year 2026.